Capital Markets: Equity (International Firms)

Kirkland & Ellis offers a highly active ECM practice, much admired for its consistency and visibility on high-profile deals. The team has a strong track record of acting for international and local businesses and investment banks on US and Hong Kong IPOs. It additionally handles a range of secondary offerings in Hong Kong and New York and maintains strong relationships with regulators. As a Hong Kong and New York-qualified team with Chinese language capabilities, Kirkland & Ellis is well placed to advise on listings on a variety of stock exchanges. It often advises on significant deals in China's TMT and life sciences sectors. Key clients of the firm include L Catterton Asia Acquisition, Clover Biopharmaceuticals and Wynn Macau.

"Kirkland & Ellis proactively understand the company's business and solve problems by using their understanding of the law and creativity to respond to specific matters. The service is professional and the feedback is timely."

"Commercial savviness is a strength; they are very commercially attuned to the business drivers of a transaction."

Kirkland & Ellis advised Yunkang Group on its USD140 million global offering and listing on the SEHK.

Lu Mengyu has notable experience in acting for life sciences and biotech clients, with a strong track record of advising on 18A IPOs. "Mengyu understands business and is hard-working, attentive to what customers think, enthusiastic, professional and creative." "She's the best IPO lawyer I've had the pleasure to work with."